Document ID: chunk:federal_register_of_legislation:F2020C01070:clause:3_17
Version: federal_register_of_legislation:F2020C01070
Segment Type: clause
Provision Reference: sch 3 cl 17
Character Range: 19161–20199

17  Dissolution
 (1) If:
           (a)    a tablet or capsule is a registered good that:
          (i) does not contain folic acid; or
            (ii) is not a modified-release tablet, chewable tablet, effervescent tablet, dispersible tablet or modified-release capsule; and
           (b)    a default standard in relation to any active ingredient contained in that tablet or capsule specifies a dissolution test for the relevant dosage form;
then the dissolution test specified for the tablet or capsule is:
           (c)    the dissolution test specified in the default standard mentioned in paragraph (1)(b); or
           (d)    another dissolution test that is suitable for the tablet or capsule.
 (2) If the tablet or capsule is a modified-release tablet or capsule, then a test for dissolution that demonstrates the appropriate release of each active ingredient must be performed.
Note: A dissolution test is specified for tablets and capsules that are registered goods or listed goods, containing folic acid: see section 15.